

우울증 환자에게 benzodiazepine 처방

서울특별시 보라매병원
신지윤


개요

- 우울증에서 benzodiazepine를 사용하는 경우
- 우울증 치료 가이드라인에서의 BDZ 처방
- Cochrane systemic review
- Benzodiazepine의 사용과 tapering

우울증에서 benzodiazepine (BDZ)를 사용하는 경우

- Agitation
 - **Suicidality ↑**
- Generalized anxiety disorder
- Panic disorder
- Insomnia


우울증과 불안장애의 공존



- 증상 심각도 ↑
- 기능 수준 ↓
- 치료 반응성 ↓
- 질병이환 기간 ↑
- 재발율 ↑
- 자살위험성 ↑

Comorbidity Patterns of Anxiety and Depressive Disorders in a Large Cohort Study: the Netherlands Study of Depression and Anxiety (NESDA)

Femke Lamers, PhD; Patricia van Oppen, PhD; Hannie C. Comijs, PhD; Johannes H. Smit, PhD; Philip Spinhoven, PhD; Anton J. L. M. van Balkom, MD, PhD; Willem A. Nolen, MD, PhD; Frans G. Zitman, MD, PhD; Aartjan T. F. Beekman, MD, PhD; and Brenda W. J. H. Penninx, PhD




- Large cohort, N=1,783
- 공존과 관련 인자
 - Childhood trauma
 - Higher neuroticism
 - Earlier onset of 1st disorder
 - Longer duration of depressive and/or anxiety symptoms
 - Higher symptom severity

Comorbidity Patterns of Anxiety and Depressive Disorders in a Large Cohort Study: the Netherlands Study of Depression and Anxiety (NESDA)

Femke Lamers, PhD; Patricia van Oppen, PhD; Hannie C. Comijs, PhD; Johannes H. Smit, PhD; Philip Spinhoven, PhD; Anton J. L. M. van Balkom, MD, PhD; Willem A. Nolen, MD, PhD; Frans G. Zitman, MD, PhD; Aartjan T. F. Beekman, MD, PhD; and Brenda W. J. H. Penninx, PhD

Current anxiety d/o: 67%

A lifetime comorbid anxiety d/o: 75%



Current depressive d/o: 63%

A lifetime comorbid depressive d/o: 81%

- 57%에서는 불안이 선행
- 18%에서는 우울이 선행

우울증 치료 가이드라인에서의 BDZ 처방

- 현 가이드라인에서는 antidepressant (AD) 단독치료가 1st line pharmacological treatment 에 해당함 (APA 2010; BAP 2015; Baure 2002; NICE 2009)
- 일부 가이드라인에서는 BDZ + AD를 **불안 또는 불면**이 동반된 경우 사용할 수 있는 **제한된 가이드**를 제시함 (APA 2010; BAP 2015, NICE 2009)
 - 동시에 BDZ는 항우울 효과가 없는 것도 함께 명시함 (APA 2010; NICE 2009)
 - BDZ 사용에 따른 다양한 부작용 때문

BDZ의 side effect

- Tolerance, and dependence
- Nocturnal confusion & falls
- Negative effects on cognitive functioning (memory impairment)
- Hangover effects, impairments in driving capability
- Rebound insomnia after withdrawal

임상현장에서의 BZD 처방

- 60%의 정신과 우울증 환자에서 첫 클리닉 방문시 BDZ를 처방
받음 (Furukawa 2000, Japan)
- 지난 12개월간 우울 삽화를 경험한 49.3%에서 AD+BDZ를 사용
함 (Sanyal 2011, Canada)

[Intervention Review]

Antidepressants plus benzodiazepines for adults with major depression

Yusuke Ogawa¹, Nozomi Takeshima², Yu Hayasaka², Aran Tajika³, Norio Watanabe², David Streiner⁴, Toshi A Furukawa²

¹Department of Healthcare Epidemiology, School of Public Health in the Graduate School of Medicine, Kyoto University, Kyoto, Japan.


²Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine/School of Public Health, Kyoto, Japan.

³Department of Psychiatry, Kyoto University Hospital, Kyoto, Japan. ⁴Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Canada


- 2019년도 Cochrane systemic review
- 10 Randomised controlled trials (n = 731)
 - Major depression adults
 - **Combined AD + BDZ vs. AD alone**

**Analysis 1.1. Comparison 1 Combination versus antidepressant (AD) alone:
depressive severity, Outcome 1 Early phase (2 weeks, range 1–4 weeks).**


- Early phase: 2 weeks
- Acute phase: 8 weeks
- Continuous phase: >12 weeks



**Analysis 1.2. Comparison 1 Combination versus antidepressant (AD) alone:
depressive severity, Outcome 2 Acute phase (8 weeks, range 5–12 weeks).**




Analysis 1.3. Comparison 1 Combination versus antidepressant (AD) alone: depressive severity, Outcome 3 Continuous phase (> 12 weeks).




Analysis 3.1. Comparison 3 Combination versus antidepressant (AD) alone: response in depression, Outcome 1 Early phase (2 weeks, range 1–4 weeks).


50% reduction in depression severity measures or CGI



Analysis 3.2. Comparison 3 Combination versus antidepressant (AD) alone: response in depression, Outcome 2 Acute phase (8 weeks, range 5–12 week).




Analysis 3.3. Comparison 3 Combination versus antidepressant (AD) alone: response in depression, Outcome 3 Continuous phase (> 12 weeks).




Analysis 4.1. Comparison 4 Combination versus antidepressant (AD) alone: remission in depression, Outcome 1 Early phase (2 weeks, range 1-4 weeks).


7 \geq on HRSD or 11 \geq MADRS
CGI 기준




Analysis 4.2. Comparison 4 Combination versus antidepressant (AD) alone: remission in depression, Outcome 2 Acute phase (8 weeks, range 5–12 weeks).




Analysis 4.3. Comparison 4 Combination versus antidepressant (AD) alone: remission in depression, Outcome 3 Continuous phase (> 12 weeks).



Analysis 5.1. Comparison 5 Combination versus antidepressant (AD) alone: anxiety severity, Outcome 1 Early phase (2 weeks, range 1–4 weeks).



**Analysis 5.2. Comparison 5 Combination versus antidepressant (AD) alone:
anxiety severity, Outcome 2 Acute phase (8 weeks, range 5–12 weeks).**



Summary of findings for the main comparison. Antidepressants plus benzodiazepines compared to antidepressants alone for major depression in adults

Antidepressants plus benzodiazepines compared to antidepressants alone for major depression in adults

Patient or population: people with major depression

Setting: inpatients and outpatients

Intervention: antidepressants + benzodiazepines

Comparison: antidepressants alone

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	Nº of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with an- tidepressants alone	Risk with antidepressants plus benzodi- azepines				
Depression severity: early phase (2 weeks, range 1–4 weeks) Follow-up: range 1–4 weeks	—	The mean depression severity in the early phase in the combination group was 0.25 standard deviations lower (0.46 lower to 0.03 lower).	—	598 (10 RCTs)	⊕⊕⊕ Moderate^a	—
Depression severity: acute phase (8 weeks, range 5–12 weeks)	—	The mean depression severity in the acute phase in the combination group was 0.18 standard deviations lower (0.40 lower to 0.03 higher).	—	347 (7 RCTs)	⊕⊕⊕ Low^{a,b}	—
Depression severity: continuous phase (> 12 weeks)	—	The mean depression severity in the continuous phase in the combination groups was 0.21 standard deviations lower (0.76 lower to 0.35 higher)	—	50 (1 RCT)	⊕⊕⊕ Low^{a,b}	—
Acceptability of treat- ment (dropout for any reason)	Study population 332 per 1000 253 per 1000 (180 to 356)		RR 0.76 (0.54 to 1.07)	731 (10 RCTs)	⊕⊕⊕ Moderate^a	—
	Moderate 200 per 1000 152 per 1000 (108 to 214)					

Anxiety severity: early phase (2 weeks, range 1–4 weeks)	—	The mean depression severity in early phase in the combination groups was 0.76 standard deviations lower (1.67 lower to 0.14 higher)	—	129 (3 RCTs)	⊕⊕⊕ Very low^{a,b,c}	—
Adverse effects (dropouts)	Study population	RR 0.54 (0.32 to 0.90)	731 (10 RCTs)	⊕⊕⊕ Moderate^a	—	

***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: confidence interval; **OR:** odds ratio; **RR:** risk ratio.

GRADE Working Group grades of evidence

High quality: we are very confident that the true effect lies close to that of the estimate of the effect.

Moderate quality: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low quality: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.

Very low quality: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

^aWe downgraded the evidence by one level because of risk of bias. Studies were described as "double-blind", but information on the procedure followed to guarantee the blindness, and if blinding was successful, was not reported in all randomised controlled trials. Also, information on randomisation procedures and allocation concealment was lacking in all studies. Moreover, half of the included studies had high attrition rate.

^bWe downgraded the evidence by one level because of low number of participants included in the analysis and 95% confidence interval included both no effect and appreciable benefit.

^cWe downgraded the evidence by one level because of high heterogeneity between studies.

요약

• Combined AD + BDZ vs. AD alone

- Early phase (1-4 weeks) 한정
- Depression severity, response in depression, remission in depression
에 더 유효
- Anxiety severity에 대해서는 차이가 없음
- Acute phase, prolonged phase 에서는 차이가 없음

[Intervention Review]

Antidepressants plus benzodiazepines for adults with major depression

Yusuke Ogawa¹, Nozomi Takeshima², Yu Hayasaka², Aran Tajika³, Norio Watanabe², David Streiner⁴, Toshi A Furukawa²

¹Department of Healthcare Epidemiology, School of Public Health in the Graduate School of Medicine, Kyoto University, Kyoto, Japan.

²Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine/School of Public Health, Kyoto, Japan. ³Department of Psychiatry, Kyoto University Hospital, Kyoto, Japan. ⁴Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Canada

BDZ의 half-life

- Anxiety d/o 동반된 경우
 - Long acting BDZ at bedtime
 - Relatively shorter BDZ during daytime
- Sleep-maintenance difficulties
 - Long acting BDZ
- Sleep-onset difficulties
 - Short acting BDZ

Table 1. Pharmacologic Classification and Half-Lives of Representative Benzodiazepines.*

Benzodiazepine	Substance Half-Life	Metabolite Half-Life
	hours	
Hypnotic agents		
Long half-life: flurazepam	2–3	≤100
Intermediate half-life		
Flunitrazepam	10–30	20–30
Nitrazepam	18–30	—
Short half-life		
Brotizolam	3–6	3–6
Lormetazepam	8–14	8–14
Temazepam	7–14	4–15
Very short half-life: triazolam	1.5–5	—
Anxiolytic agents		
Long half-life		
Diazepam	24–48	≤200
Chlordiazepoxide	6–38	≤200
Clobazam	50	20
Clorazepate dipotassium	2–2.5	≤200
Medazepam	2–2.5	≤200
Prazepam	1–3	≤200
Short-to-intermediate half-life with active metabolites		
Lorazepam	2	—
Oxazepam	30	—
Alprazolam	12–15	1
Bromazepam	15	6

* Data on hypnotic agents are from Soyka,⁶ Benkert and Hippius,⁹ and Julien,¹⁰ and data on anxiolytic agents are from Benkert and Hippius.⁹ Dashes denote no active metabolite.



Table 29.9-1
Preparations and Doses of Medications Acting on the Benzodiazepine Receptor Available in the United States

Medication	Brand Name	Dose Equivalent	Usual Adult Dose (mg)	How Supplied
Diazepam	Valium	5	2.5–40.0	2-, 5-, and 10-mg tablets 15-mg slow-release tablets
Clonazepam	Klonopin	0.25	0.5–4.0	0.5-, 1.0-, and 2.0-mg tablets
Alprazolam	Xanax	0.5	0.5–6.0	0.25-, 0.5-, 1.0-, and 2.0-mg tablets 1.5-mg sustained-release tablet
Lorazepam	Ativan	1	0.5–6.0	0.5-, 1.0-, and 2.0-mg tablets 4 mg/mL parenteral
Oxazepam	Serax	15	15–120	7.5-, 10.0-, 15.0-, and 30.0-mg capsules 15-mg tablets
Chlordiazepoxide	Librium	25	10–100	5-, 10-, and 25-mg capsules and tablets
Clorazepate	Tranxene	7.5	15–60	3.75-, 7.50-, and 15.00-mg tablets 11.25- and 22.50-mg slow-release tablets
Midazolam	Versed	0.25	1–50	5 mg/mL parenteral 1-, 2-, 5-, and 10-mL vials
Flurazepam	Dalmane	15	15–30	15- and 30-mg capsules
Temazepam	Restoril	15	7.5–30.0	7.5-, 15.0-, and 30.0-mg capsules
Triazolam	Halcion	0.125	0.125–0.250	0.125- and 0.250-mg tablets
Estazolam	ProSom	1	1–2	1- and 2-mg tablets
Quazepam	Doral	5	7.5–15.0	7.5- and 15.0-mg tablets
Zolpidem	Ambien	10	5–10	5- and 10-mg tablets
	Ambien CR	5	6.25–12.5	6.25- and 12.5-mg tablets
Zaleplon	Sonata	10	5–20	5- and 10-mg capsules
Eszopiclone	Lunesta	1	1–3	1-, 2- and 3-mg tablets
Flumazenil	Romazicon	0.05	0.2–0.5 per min	0.1 mg/mL 5- and 10-mL vials

BDZ for anxiety

- 1st line pharmacology tx: SSRI
- AD 사용 초반 anxiety, agitation 유발 가능성
- BDZ는 불안을 수분 이내에 호전시킴

Bandelow et al., 2023

Table 7. Dosing recommendations for medication treatment of anxiety disorders, OCD and PTSD.

Treatment	Examples	Recommended daily dose for adults
SSRIs	Citalopram Escitalopram Fluoxetine Fluvoxamine Paroxetine Sertraline	20–40 mg ^a 10–20 mg ^a 20–40 mg 100–300 mg 20–60 mg 50–200 mg
SNRIs	Venlafaxine Duloxetine	75–225 mg 60–120 mg
TCAs	Amitriptyline Clomipramine Imipramine Desipramine Lofepramine	75–150 mg 75–250 mg 75–250 mg 100–300 mg 70–210 mg
Benzodiazepines	Alprazolam Bromazepam Clonazepam Diazepam Lorazepam	1.5–8 mg 1.5–6 mg 1–4 mg 5–20 mg 2–8 mg
SSRI/5-HT _{1A} receptor partial agonist SARI NaSSA MAOI RIMA MT ₁ /MT ₂ agonist/5-HT _{2C} antagonist Calcium channel modulators	Vilazodone Trazodone Mirtazapine Phenelzine Moclobemide Agomelatine Pregabalin Gabapentin	20–40 mg 150–600 mg 30–60 mg 45–90 mg 300–600 mg 25–50 mg 150–600 mg 600–3600 mg
Atypical antipsychotics	Quetiapine Risperidone Olanzapine Hydroxyzine OPIPramol Buspirone Lamotrigine Silexan Prazosin	50–300 mg 0.5–6 mg 2.5–20 mg 37.5–75 mg 50–150 mg 15–60 mg 25–500 mg 80–160 mg 1–10 mg
Antihistamine Tricyclic anxiolytic Azapirone Anticonvulsant Lavender oil extract α ₁ -Antagonist		

BDZ for insomnia symptoms

- BDZ & Z-drug는 **4주 이내**의 short-term 사용 권고 (European Insomnia Guideline, 2023)
- 대부분의 meta-analyses에서 **최대 4주 이내** 사용시 수면에 대한 긍정적 효과가 있었음.

Characteristics of Benzodiazepine Receptor Agonists Commonly Used for Insomnia

Generic Name	Receptor Binding Specificity	Dose Range (mg)	Elimination Half-Life (hr)	Metabolism
Estazolam	Nonspecific	1–2	10–24	CYP3A
Flurazepam	Nonspecific	15–30	48–120 ^a	CYP3A4
Lorazepam ^b	Nonspecific	0.5–2	8–12	CYP3A4
Quazepam	Nonspecific	7.5–15	39–73 ^a	Not available
Temazepam	Nonspecific	15–30	8–20	None
Triazolam	Nonspecific	0.125–0.25	2–6	CYP3A4
Eszopiclone	GABA _A α 1,2,3	1–3	6	CYP3A4, CYP2E1
Zaleplon	GABA _A α 1	5–20	1	Minor: CYP3A4
Zolpidem	GABA _A α 1	5–10	1.5–2.4	CYP3A4, CYP2C9
Zolpidem extended-release	GABA _A α 1	6.25–12.5	1.6–4.5	CYP3A4, CYP2C9
Zolpidem sublingual tablet	GABA _A α 1	5–10	1.5–2.4	CYP3A4, CYP2C9
Zolpidem oral spray	GABA _A α 1	5–10	1.5–2.4	CYP3A4, CYP2C9
Zolpidem sublingual lozenge	GABA _A α 1	1.75–3.5	1.5–2.4	CYP3A4, CYP2C9

Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline

Michael J. Sateia, MD¹; Daniel J. Buysse, MD²; Andrew D. Krystal, MD, MS³; David N. Neubauer, MD⁴; Jonathan L. Heald, MA⁵

Table 5—Summary of “critical” outcomes by indication.

Recommended for Treating Sleep Onset Insomnia	
Eszopiclone	Sleep latency: Mean reduction was 14 min greater, compared to placebo (95% CI: 3 to 24 min reduction); Quality of sleep* : Moderate-to-Large ^a improvement in quality of sleep, compared to placebo; Side effects : See Recommendation 2, “Harms” <i>This recommendation is based on trials of 2 mg and 3 mg doses of eszopiclone.</i>
Ramelteon	Sleep latency: Mean reduction was 9 min greater, compared to placebo (95% CI: 6 to 12 min reduction); Quality of sleep* : No improvement ^b in quality of sleep, compared to placebo; Side effects : See Recommendation 7, “Harms” <i>This recommendation is based on trials of 8 mg doses of ramelteon.</i>
Temazepam	Sleep latency: Mean reduction was 37 min greater, compared to placebo (95% CI: 21 to 53 min reduction); Quality of sleep* : Small ^a improvement in quality of sleep, compared to placebo; Side effects : See Recommendation 6, “Harms” <i>This recommendation is based on trials of 15 mg doses of temazepam.</i>
Triazolam	Sleep latency* : Mean reduction was 9 min greater, compared to placebo (95% CI: 4 to 22 min reduction); Quality of sleep* : Moderate ^c improvement in quality of sleep, compared to placebo; Side effects : See Recommendation 5, “Harms” <i>This recommendation is based on trials of 0.25 mg doses of triazolam.</i>
Zaleplon	Sleep latency: Mean reduction was 10 min greater, compared to placebo (95% CI: 0 to 19 min reduction); Quality of sleep* : No improvement ^b in quality of sleep, compared to placebo; Side effects : See Recommendation 3, “Harms” <i>This recommendation is based on trials of 5 mg and 10 mg doses of zaleplon.</i>
Zolpidem	Sleep latency: Mean reduction was 5–12 min greater, compared to placebo (95% CI: 0 to 19 min reduction); Quality of sleep* : Moderate ^a improvement in quality of sleep, compared to placebo; Side effects : See Recommendation 4, “Harms” <i>This recommendation is based on trials of 10 mg doses of zolpidem.</i>

Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline

Michael J. Sateia, MD¹; Daniel J. Buysse, MD²; Andrew D. Krystal, MD, MS³; David N. Neubauer, MD⁴; Jonathan L. Heald, MA⁵

Recommended for Treating Sleep Maintenance Insomnia	
Doxepin	Total sleep time: Mean improvement was 26–32 min longer, compared to placebo (95% CI: 18 to 40 min improvement); Wake after sleep onset: Mean reduction was 22–23 min greater, compared to placebo (95% CI: 14 to 30 min reduction); Quality of sleep* : Small-to-moderate ^a improvement in quality of sleep, compared to placebo; Side effects: See Recommendation 8, “Harms” <i>This recommendation is based on trials of 3 mg and 6 mg doses of doxepin.</i>
Eszopiclone	Total sleep time: Mean improvement was 28–57 min longer, compared to placebo (95% CI: 18 to 76 min improvement); Wake after sleep onset: Mean reduction was 10–14 min greater, compared to placebo (95% CI: 2 to 18 min reduction); Quality of sleep* : Moderate-to-Large ^a improvement in quality of sleep, compared to placebo; Side effects: See Recommendation 2, “Harms” <i>This recommendation is based on trials of 2 mg and 3 mg doses of eszopiclone.</i>
Temazepam	Total sleep time: Mean improvement was 99 min longer, compared to placebo (95% CI: 63 to 135 min improvement); Wake after sleep onset: Not reported; Quality of sleep* : Small ^a improvement in quality of sleep, compared to placebo; Side effects: See Recommendation 6, “Harms” <i>This recommendation is based on trials of 15 mg doses of temazepam.</i>
Suvorexant	Total sleep time: Mean improvement was 10 min longer, compared to placebo (95% CI: 2 to 19 min improvement); Wake after sleep onset: Mean reduction was 16–28 min greater, compared to placebo (95% CI: 7 to 43 min reduction); Quality of sleep* : Not reported; Side effects: See Recommendation 1, “Harms” <i>This recommendation is based on trials of 10, 15/20, and 20 mg doses of suvorexant.</i>
Zolpidem	Total sleep time: Mean improvement was 29 min. longer, compared to placebo (95% CI: 11 to 47 min. improvement); Wake after sleep onset: Mean reduction was 25 min greater, compared to placebo (95% CI: 18 to 33 min reduction); Quality of sleep* : Moderate ^a improvement in quality of sleep, compared to placebo; Side effects: See Recommendation 4, “Harms” <i>This recommendation is based on trials of 10 mg doses of zolpidem.</i>

Table 3. Clinical Symptoms and Complications of Benzodiazepine Withdrawal.*

Psychopathologic symptoms
Increased anxiety
Nervousness
Sleep disorders
Inner restlessness
Depressive symptoms
Irritability
Psychosis-like conditions, delirium
Depersonalization and derealization
Confusion
Vegetative symptoms
Trembling
Sweating
Nausea and vomiting
Motor agitation
Dyspnea
Increased heart rate
Elevated blood pressure
Headaches
Muscle tension
Neurologic and physical complications
Increased risk of seizures
Impairment of voluntary movements
Cognitive impairments
Impairment of memory
Pronounced perceptual impairments
Hyperacusis
Photophobia
Hypersomnia
Dysesthesia, kinesthetic disorders, muscle twitching and fasciculations

Tapering BDZ medications

- 4-6주 이상의 기간 동안에 서서히 감량
 - Seizure, severe withdrawal symptoms를 줄이기 위함
- 매주 용량의 50%를 감량하도록 권고
- Short-acting BZD withdrawal의 경우 long-acting BZD withdrawal에서보다 drop-out이 높음
- Motivation enhancement 가 필요함

요약

- 우울증에는 불안, 불면이 흔하게 동반됨
- BDZ과 AD의 병용은 4주 이내 단기 사용시 우울 심각도, response, remission에서 효과가 있음
- BDZ의 단기적 사용은 불안, 불면에 효과가 있음
- 추후 BDZ를 taper out하는 것에 대한 고민이 필요함

감사합니다